Related Experiment Video
Updated: Aug 17, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Atrial fibrillation and thromboembolic stroke
1Hebrew Hospital Home, Bronx, NY 10475.
Insights
Long-term oral warfarin is recommended for atrial fibrillation patients with a history of embolism or valve disease to prevent stroke. Aspirin is an alternative for some patients, while younger lone atrial fibrillation patients may not need anticoagulation.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) is a common arrhythmia associated with a high risk of thromboembolic stroke.
- Effective anticoagulation strategies are crucial for stroke prevention in AF patients.
- Current guidelines recommend tailored approaches based on patient risk factors and comorbidities.
Purpose of the Study:
- To outline evidence-based recommendations for anticoagulation and rate control in patients with atrial fibrillation.
- To differentiate treatment strategies based on AF type, patient age, and specific risk factors.
- To provide guidance on the use of warfarin, aspirin, and rate-controlling medications.
Main Methods:
- Review of existing clinical guidelines and landmark studies on anticoagulation in atrial fibrillation.
- Analysis of patient subgroups including those with valvular heart disease, nonvalvular AF, and lone AF.
- Evaluation of pharmacological agents for rate control and rhythm management.
Main Results:
- Long-term oral warfarin is indicated for AF patients with a history of systemic embolism, mitral valve disease, nonvalvular AF, or mitral annular calcium to reduce thromboembolic stroke.
- Aspirin (325 mg/d) is an alternative for nonvalvular AF patients with warfarin contraindications or low thromboembolic risk if younger than 75.
- Elderly patients with lone AF should receive low-dose warfarin; younger lone AF patients (<60 years) should not receive anticoagulants.
- Rate control can be achieved with digoxin, verapamil, diltiazem, and propranolol.
- Antiarrhythmic drugs are not routinely recommended, but propranolol may be used for ventricular arrhythmias or post-conversion.
Conclusions:
- Anticoagulation choice in atrial fibrillation requires careful consideration of individual patient risk factors and contraindications.
- Warfarin remains a primary agent for stroke prevention in high-risk AF populations.
- Rate control agents are effective for managing ventricular response in AF, with specific indications for propranolol.
Abstract:
Long-term oral warfarin should be administered to patients with atrial fibrillation who have a history of systemic embolism, mitral valve disease, nonvalvular atrial fibrillation, or mitral annular calcium to reduce the incidence of thromboembolic stroke. Aspirin 325 mg/d may be given to patients with non-valvular atrial fibrillation who have contraindications to warfarin and to patients with nonvalvular atrial fibrillation younger than 75 years of age who have a low risk of systemic thromboembolism. Patients with lone atrial fibrillation younger than 60 years of age should not receive anticoagulants. However, low-dose oral warfarin should be given to elderly patients with lone atrial fibrillation. Digoxin, verapamil, diltiazem, and propranolol may be used to control ventricular rate in atrial fibrillation. I would not routinely use antiarrhythmic drugs but would use propranolol in patients with atrial fibrillation with ventricular arrhythmias or after conversion of atrial fibrillation to sinus rhythm.
More Related Videos
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism I: Introduction
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Ischemic Stroke l: Introduction
Pulmonary Embolism I: Introduction

